FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Chugai Pharmaceutical Co., Ltd. Stock AnalysisComprehensive stock analysis for Chugai Pharmaceutical Co., Ltd. (CHGCY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCHGCY
CHGCY
Chugai Pharmaceutical Co., Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CHGCY
Home🔹Stocks🔹Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

CHGCY•OTC

Chugai Pharmaceutical Co., Ltd.

CHGCY•OTC
Market cap
$109.97B
Sentiment

Your view on CHGCY

Mkt Cap
$109.97B
Sentiment
Your view
CHGCY
Chugai Pharmaceutical Co., Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CHGCY
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Chugai Pharmaceutical Co., Ltd.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Osamu Okuda
Headquarters
Nihonbashi Mitsui Tower, Tokyo, JP
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Osamu Okuda
Headquarters
Nihonbashi Mitsui Tower, Tokyo, JP
Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News